WS Management’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-28,797
Closed -$292K 64
2023
Q4
$292K Hold
28,797
0.02% 66
2023
Q3
$225K Hold
28,797
0.02% 67
2023
Q2
$237K Hold
28,797
0.02% 62
2023
Q1
$209K Hold
28,797
0.02% 57
2022
Q4
$255K Hold
28,797
0.02% 63
2022
Q3
$352K Hold
28,797
0.03% 67
2022
Q2
$341K Hold
28,797
0.03% 70
2022
Q1
$548K Hold
28,797
0.03% 64
2021
Q4
$765K Hold
28,797
0.06% 57
2021
Q3
$1.18M Hold
28,797
0.13% 62
2021
Q2
$1.63M Hold
28,797
0.16% 63
2021
Q1
$1.21M Sell
28,797
-1,466
-5% -$83.5K 0.13% 58
2020
Q4
$2.12M Hold
30,263
0.22% 46
2020
Q3
$849K Hold
30,263
0.09% 56
2020
Q2
$895K Sell
30,263
-5,211
-15% -$136K 0.11% 49
2020
Q1
$703K Sell
35,474
-1,785
-5% -$45K 0.08% 56
2019
Q4
$1.1M Hold
37,259
0.09% 50
2019
Q3
$847K Sell
37,259
-4,113
-10% -$102K 0.07% 59
2019
Q2
$1.02M Sell
41,372
-4,898
-11% -$117K 0.07% 62
2019
Q1
$1.13M Sell
46,270
-6,244
-12% -$141K 0.07% 61
2018
Q4
$1.2M Sell
52,514
-34,251
-39% -$932K 0.06% 75
2018
Q3
$2.76M Hold
86,765
0.09% 74
2018
Q2
$3.11M Buy
+86,765
New +$3.07M 0.09% 73

Other funds holding EDIT

WS Management's EDIT Position: Q1 2024 in Review

WS Management sold out of Editas Medicine (EDIT) in Q1 2024, closing a stake of 28,797 shares — an estimated $292K sold.

WS Management first reported a position in EDIT in Q2 2018 and held it in 23 quarters. The position peaked at $3.11M in Q2 2018. 225 funds tracked by Wall St. Rank hold EDIT as of Q1 2024.

  • WS Management reported no remaining Editas Medicine position as of Q1 2024 after selling out during the quarter.
  • WS Management sold 28,797 Editas Medicine shares in Q1 2024, an estimated $292K.
  • WS Management first reported a position in Editas Medicine in Q2 2018 and held it in 23 quarters.
  • WS Management's Editas Medicine position peaked at $3.11M in Q2 2018.
  • 225 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2024.

Based on WS Management's 13F filing for Q1 2024, filed 14 May 2024.